Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Clinical trial NCT04920708 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04920708
Sponsor: Royal Marsden NHS Foundation Trust
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer ER+ Breast Cancer Advanced Breast Cancer

Start date: 2022-12-28
Primary completion: 2027-06-01
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.